There are currently 4 active clinical trials seeking participants for Hypertriglyceridemia research studies. The states with the highest number of trials for Hypertriglyceridemia participants are Florida, California, Texas and Ontario.
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-3001 (NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (NCT06347133). All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Research Site 1, Miami Lakes, Florida +6 locations
Conditions: Hypertriglyceridemia
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2025
Locations: Lifeline Primary Care/Avacare, Lilburn, Georgia +8 locations
Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Recruiting
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2)... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
11/18/2024
Locations: Jubilee Clinical Research, Inc., Las Vegas, Nevada
Conditions: Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Impact of Foods on Bile Acids, Metabolites, and Inflammation
Recruiting
Dietary incorporation of pulse crops may be an effective way to lower unhealthy elevations in serum bile acids. These elevations play a direct role in promoting obesity-related diseases estimated to be present in about one third of the US adult population, including non-alcoholic fatty liver disease and type 2 diabetes. The overarching hypothesis for this study is that pulse consumption increases bile acid secretion and excretion, which will decrease toxicity linked to excess accumulation of bil... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2023
Locations: Nutrition Research Laboratory, Bozeman, Montana
Conditions: Inflammation, Hypertriglyceridemia, Metabolic Disease, Lipid Metabolism Disorder, Hyperlipidemias, Bile Acid Malabsorption